In short
A new clinical trial is underway to evaluate the effectiveness of Lu AG22515, a Human (Scfv)2-Fab Fusion Protein Against CD40L, in treating moderate-to-severe Thyroid Eye Disease (TED). This open-label, single-group study aims to assess the drug's impact on reducing proptosis, a common symptom of TED, as well as its safety and tolerability in adult patients. The trial represents an important step in exploring potential new therapies for this challenging autoimmune condition.
At a glance
- Trial Name
- 2023-508693-29-00
- Drug Name
- Lu AG22515 (Human (Scfv)2-Fab Fusion Protein Against CD40L)
- Condition
- Moderate-to-severe Thyroid Eye Disease (TED)
- Trial Type
- Interventional, open-label, single-group, long-term follow-up
- Primary Endpoint
- Change in proptosis from Baseline to Week 24 in the trial eye
- Key Inclusion Criteria
- TED symptoms onset <12 months, proptosis ≥3 mm above normal, Clinical Activity Score ≥3
- Key Exclusion Criteria
- Decreased visual acuity due to optic neuropathy, previous orbital irradiation or surgery for TED
- Secondary Endpoints
- Pharmacokinetics, safety, immunogenicity
What is Lu AG22515?
Lu AG22515 is a new medication being studied for the treatment of moderate-to-severe Thyroid Eye Disease (TED). It is classified as a HUMAN (SCFV)2-FAB FUSION PROTEIN AGAINST CD40L, which is a type of engineered protein designed to target specific molecules in the body. This medication is currently in the experimental stage and is being tested in clinical trials to evaluate its effectiveness and safety.
Thyroid Eye Disease: An Overview
Thyroid Eye Disease, also known as TED, is a condition associated with Graves' disease, an autoimmune disorder affecting the thyroid gland. TED causes inflammation and swelling of the tissues around the eyes, leading to symptoms such as bulging eyes (proptosis), eye redness, and in severe cases, vision problems.
How Lu AG22515 Works
Lu AG22515 is designed to target a specific molecule called CD40L, which plays a role in the immune system. By interfering with CD40L, the medication aims to reduce the inflammation and swelling associated with Thyroid Eye Disease. This could potentially lead to improvements in symptoms, particularly the bulging of the eyes (proptosis).
Clinical Trial Details
A clinical trial is currently underway to study Lu AG22515. Here are some key details about the trial:
- Trial Type: This is an interventional, open-label, single-group, long-term follow-up trial.
- Phase: It is classified as a therapeutic exploratory phase IB trial.
- Main Objective: The primary goal is to evaluate how effective Lu AG22515 is in reducing proptosis (eye bulging) in patients with TED.
- Duration: The trial will assess changes in proptosis from the start of treatment up to 24 weeks.
Eligibility Criteria
To participate in this trial, patients must meet certain criteria. Some key inclusion criteria are:
- Having Graves' disease associated Thyroid Eye Disease with symptoms starting less than 12 months before the trial.
- Showing significant eye bulging (proptosis) of at least 3 millimeters above normal.
- Having a Clinical Activity Score (CAS) of 3 or higher, which indicates active inflammation.
There are also several exclusion criteria, such as:
- Having severe vision problems due to optic nerve involvement.
- Previous orbital radiation or surgery for TED.
- Certain medications or recent vaccinations.
Potential Benefits
If successful, Lu AG22515 could offer several benefits for patients with moderate-to-severe Thyroid Eye Disease:
- Reduction in eye bulging (proptosis).
- Potential improvement in other TED symptoms.
- A new treatment option for patients who haven't responded well to other therapies.
Safety Considerations
As with any new medication, safety is a crucial aspect of the clinical trial. The researchers will be closely monitoring:
- Any side effects that occur during treatment (known as Treatment-Emergent Adverse Events or TEAEs).
- Changes in laboratory test results, vital signs, weight, and heart activity (ECG).
- The body's immune response to the medication (immunogenicity).
Future Prospects
This clinical trial is an important step in developing Lu AG22515 as a potential treatment for Thyroid Eye Disease. If the results are positive, it could lead to further studies and potentially a new treatment option for patients with this condition. The company conducting the trial, Lundbeck, has committed to sharing the data from this clinical trial once the product is approved in Europe and/or the United States.